EVENT
Moderna, Pfizer, and the mRNA Precedent
The 2020–2022 commercialization of mRNA vaccine technology — thirty years of publicly funded research, seventy billion in private returns, zero direct public participation in the upside.
The mRNA vaccine commercialization during the COVID-19 pandemic provides the cleanest recent example of Mazzucato's public-risk-private-reward pattern at civilizational scale. The foundational research on messenger RNA as a therapeutic platform was conducted over three decades, primarily in university laboratories funded by the NIH and equivalent agencies. Katalin Karikó's work on modified nucleosides — which made mRNA vaccines feasible — was considered so commercially unpromising that she was repeatedly denied tenure at the University of Pennsylvania. Conservative estimates place total public investment in mRNA-related research at over thirty billion dollars. Moderna and Pfizer's combined COVID vaccine revenue exceeded seventy billion dollars in the first two years. The NIH, which funded the foundational research for three decades, received no direct equity return, no royalty stream, and no financial participation in the commercial success. The pattern serves as both evidence and warning for the AI transition, which is reproducing the same structural arrangement at larger scale and faster speed.
